Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

55,202 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Identification of a RAS-activating TMEM87A-RASGRF1 Fusion in an Exceptional Responder to Sunitinib with Non-Small Cell Lung Cancer.
Cooper AJ, Kobayashi Y, Kim D, Clifford SE, Kravets S, Dahlberg SE, Chambers ES, Li J, Rangachari D, Nguyen T, Costa DB, Rabin MS, Wagle N, Sholl LM, Jänne PA, Oxnard GR. Cooper AJ, et al. Among authors: kim d. Clin Cancer Res. 2020 Aug 1;26(15):4072-4079. doi: 10.1158/1078-0432.CCR-20-0397. Epub 2020 Apr 20. Clin Cancer Res. 2020. PMID: 32312893 Free PMC article. Clinical Trial.
The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research.
Painter CA, Jain E, Tomson BN, Dunphy M, Stoddard RE, Thomas BS, Damon AL, Shah S, Kim D, Gómez Tejeda Zañudo J, Hornick JL, Chen YL, Merriam P, Raut CP, Demetri GD, Van Tine BA, Lander ES, Golub TR, Wagle N. Painter CA, et al. Among authors: kim d. Nat Med. 2020 Feb;26(2):181-187. doi: 10.1038/s41591-019-0749-z. Epub 2020 Feb 10. Nat Med. 2020. PMID: 32042194
Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer.
Waks AG, Cohen O, Kochupurakkal B, Kim D, Dunn CE, Buendia Buendia J, Wander S, Helvie K, Lloyd MR, Marini L, Hughes ME, Freeman SS, Ivy SP, Geradts J, Isakoff S, LoRusso P, Adalsteinsson VA, Tolaney SM, Matulonis U, Krop IE, D'Andrea AD, Winer EP, Lin NU, Shapiro GI, Wagle N. Waks AG, et al. Among authors: kim d, d andrea ad. Ann Oncol. 2020 May;31(5):590-598. doi: 10.1016/j.annonc.2020.02.008. Epub 2020 Feb 20. Ann Oncol. 2020. PMID: 32245699 Free PMC article.
The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer.
Wander SA, Cohen O, Gong X, Johnson GN, Buendia-Buendia JE, Lloyd MR, Kim D, Luo F, Mao P, Helvie K, Kowalski KJ, Nayar U, Waks AG, Parsons SH, Martinez R, Litchfield LM, Ye XS, Yu C, Jansen VM, Stille JR, Smith PS, Oakley GJ, Chu QS, Batist G, Hughes ME, Kremer JD, Garraway LA, Winer EP, Tolaney SM, Lin NU, Buchanan SG, Wagle N. Wander SA, et al. Among authors: kim d. Cancer Discov. 2020 Aug;10(8):1174-1193. doi: 10.1158/2159-8290.CD-19-1390. Epub 2020 May 13. Cancer Discov. 2020. PMID: 32404308 Free PMC article. Clinical Trial.
Somatic and Germline Genomic Alterations in Very Young Women with Breast Cancer.
Waks AG, Kim D, Jain E, Snow C, Kirkner GJ, Rosenberg SM, Oh C, Poorvu PD, Ruddy KJ, Tamimi RM, Peppercorn J, Schapira L, Borges VF, Come SE, Brachtel EF, Warner E, Collins LC, Partridge AH, Wagle N. Waks AG, et al. Among authors: kim d. Clin Cancer Res. 2022 Jun 1;28(11):2339-2348. doi: 10.1158/1078-0432.CCR-21-2572. Clin Cancer Res. 2022. PMID: 35101884 Free PMC article.
Genomics of ERBB2-Positive Breast Cancer in Young Women Before and After Exposure to Chemotherapy Plus Trastuzumab.
Lipsyc-Sharf M, Jain E, Collins LC, Rosenberg SM, Ruddy KJ, Tamimi RM, Schapira L, Come SE, Peppercorn JM, Borges VF, Warner E, Snow C, Krop IE, Kim D, Weiss J, Zanudo JGT, Partridge AH, Wagle N, Waks AG. Lipsyc-Sharf M, et al. Among authors: kim d. JCO Precis Oncol. 2023 Jun;7:e2300076. doi: 10.1200/PO.23.00076. JCO Precis Oncol. 2023. PMID: 37364233
[No title available]
[No authors listed] [No authors listed] PMID: 37784672
A patient-driven clinicogenomic partnership for metastatic prostate cancer.
Crowdis J, Balch S, Sterlin L, Thomas BS, Camp SY, Dunphy M, Anastasio E, Shah S, Damon AL, Ramos R, Sosa DM, Small IK, Tomson BN, Nguyen CM, McGillicuddy M, Chastain PS, He MX, Cheung ATM, Wankowicz S, Tewari AK, Kim D, AlDubayan SH, Dowdye A, Zola B, Nowak J, Manarite J, Gunn IH, Olson B, Lander ES, Painter CA, Wagle N, Van Allen EM. Crowdis J, et al. Among authors: kim d. Cell Genom. 2022 Sep 14;2(9):100169. doi: 10.1016/j.xgen.2022.100169. Epub 2022 Aug 19. Cell Genom. 2022. PMID: 36177448 Free PMC article.
55,202 results
You have reached the last available page of results. Please see the User Guide for more information.